Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOGO: Tocilizumab versus methylprednisolone in active moderate-severe Graves' orbitopathy
2018-002790-22Phase 2Completed
- Sponsor
- IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in Graves' ophthalmopathy (TED) comparing RoActemra arm with Solu-Medrol arm (2 arms). Primary endpoint: Proportion of patients improved at 24 weeks. Started Mar 2019; status: completed.
02
Drugs
tocilizumabmethylprednisolone sodium succinate
03
Conditions
Graves' ophthalmopathy (TED)
Beyond the preview
Go deeper on 2018-002790-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002790-22.